Boston Partners Buys 1,860,564 Shares of Globus Medical, Inc. $GMED

Boston Partners increased its stake in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 119.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 3,415,554 shares of the medical device company’s stock after buying an additional 1,860,564 shares during the quarter. Boston Partners’ holdings in Globus Medical were worth $255,898,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of GMED. Paradigm Capital Management Inc. NY acquired a new stake in Globus Medical in the 2nd quarter valued at $70,042,000. American Capital Management Inc. bought a new stake in shares of Globus Medical in the second quarter valued at approximately $51,599,000. Hawk Ridge Capital Management LP bought a new stake in shares of Globus Medical during the 1st quarter worth $43,078,000. Arrowstreet Capital Limited Partnership grew its holdings in Globus Medical by 107.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 912,905 shares of the medical device company’s stock worth $78,656,000 after acquiring an additional 471,875 shares during the last quarter. Finally, Janus Henderson Group PLC grew its stake in Globus Medical by 4.5% during the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after purchasing an additional 328,217 shares during the period. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical Trading Down 2.8%

NYSE:GMED opened at $68.56 on Friday. The business’s 50-day moving average is $76.13 and its 200 day moving average is $82.29. The company has a market capitalization of $9.08 billion, a P/E ratio of 14.19, a P/E/G ratio of 1.09 and a beta of 0.98. Globus Medical, Inc. has a 12 month low of $68.25 and a 12 month high of $101.40.

Globus Medical (NYSE:GMED – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.03. The company had revenue of $763.72 million for the quarter, compared to analysts’ expectations of $792.39 million. Globus Medical had a return on equity of 14.43% and a net margin of 17.76%. Globus Medical’s revenue was down .7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.18 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, research analysts forecast that Globus Medical, Inc. will post 4.98 earnings per share for the current year.

Analyst Ratings Changes

GMED has been the subject of a number of analyst reports. Wall Street Zen downgraded Globus Medical from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. Zacks Research cut shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 9th. Royal Bank Of Canada dropped their price objective on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a research note on Thursday, October 1st. BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a report on Friday, November 6th. Finally, BMO Capital Markets cut shares of Globus Medical from an “outperform” rating to a “market perform” rating and cut their price target for the company from $94.00 to $78.00 in a report on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $96.08.

View Our Latest Stock Analysis on GMED

Insider Buying and Selling at Globus Medical

In related news, Director Ann Rhoads sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total value of $425,000.00. Following the completion of the transaction, the director owned 35,384 shares of the company’s stock, valued at approximately $3,007,640. The trade was a 12.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director James R. Tobin sold 41,666 shares of the stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $75.16, for a total transaction of $3,131,616.56. Following the sale, the director directly owned 15,000 shares of the company’s stock, valued at approximately $1,127,400. This trade represents a 73.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 76,666 shares of company stock valued at $5,794,017 in the last ninety days. Corporate insiders own 18.38% of the company’s stock.

Globus Medical Company Profile

(Free Report)

Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.

Further Reading

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED – Free Report).

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.